OBJECTIVE: Obesity is associated with chronic inflammation of the adipose tissue, which contributes to obesity-associated complications such as insulin resistance and type 2 diabetes. Interleukin (IL)-33 acts via its receptor ST2 and is involved in the pathogenesis of inflammatory disorders including atherosclerosis and heart disease. IL-33 has been demonstrated to promote endothelial cell inflammatory response, but also anti-inflammatory and protective actions such as T H 2 and M2 polarization of T cells and macrophages, respectively. IL-33 and ST2 have been shown to be expressed in human and murine adipose tissue. Our objective was to investigate alterations in obesity and a possible role of IL-33 in adipose tissue inflammation. SUBJECTS AND METHODS: We investigated severely obese patients (BMI440 kg m À 2 , n ¼ 20) and lean to overweight controls (BMIo30 kg m À 2 ; n ¼ 20) matched for age and sex, as well as diet-induced obese and db/db mice, in order to determine the impact of obesity on IL-33 and ST2 gene and protein expression levels in adipose tissue and blood, and their correlation with inflammatory and metabolic parameters. Furthermore, we examined the cellular source and location of IL-33 and ST2 in situ. RESULTS: IL-33 and ST2 expression levels were markedly elevated in omental and subcutaneous adipose tissue of severely obese humans and in diet-induced obese mice, but not in leptin receptor-deficient db/db mice. In addition, soluble ST2, but not IL-33 serum levels, were elevated in obesity. The main source for IL-33 in adipose tissue were endothelial cells, which, in humans, exclusively expressed ST2 on their surface. IL-33 expression strongly correlated with leptin expression in human adipose tissue. CONCLUSIONS: Expression of IL-33 and its receptor ST2 in human adipose tissue is predominantly detectable in endothelial cells and increased by severe obesity indicating an autocrine action. Thus, the adipose tissue microvasculature could participate in obesity-associated inflammation and related complications via IL-33/ST2.
INTRODUCTION
Obesity is strongly associated with inflammation that is etiologically involved in the development of insulin resistance and associated disorders such as type 2 diabetes and atherosclerosis. 1, 2 In obese patients, a chronic low-grade inflammation can be detected by increased plasma levels of C-reactive protein, inflammatory cytokines such as tumor necrosis factor-a, interleukin (IL)-6, monocyte chemoattractant protein-1, IL-8, 3 and the multifunctional protein leptin, which is considered as an adiposity signal as it circulates at levels proportional to the amount of adipose tissue and may also be regarded as an inflammatory cytokine. 4 Strikingly, inflammatory mediators cause insulin resistance and the primary site for this interaction is the adipose tissue. 5, 6 Adipose tissue is the main contributor to elevated obesity-driven systemic inflammation as well as insulin resistance. 7 The main sources of inflammatory mediators within both murine and human adipose tissue are macrophages, 8 although other cell types such as adipocytes, preadipocytes, vascular endothelial cells, T-lymphocytes and the mesothelium may also contribute. 9 IL-33 was originally named NF-HEV (nuclear factor from high endothelial venules) and is known for its interaction with nuclear chromatin, but its intracellular function still needs to be clarified. 10 IL-33 expression has been found in many different tissues, cells and organs. 11 IL-33 is a general constituent in superconfluent endothelial cells in vitro and resting endothelial cells in vivo, but is absent in subconfluent cultures, in the proinflammatory/ angiogenic environment of wound-healing and immature tumor vessels. 12 Recently, it was also shown that IL-33 mRNA is expressed in adipocytes and preadipocytes and in vitro treatment with tumor necrosis factor-a increased IL-33 mRNA levels in these cell types. 13 IL-33 is recognized as the specific ligand for orphan IL-1 receptor family member ST2.
14 Hence, secretion of IL-33 is essential to activate its receptor, although its mRNA is translated without a signal sequence as it is true for other IL-1 family members, IL-1b and IL-18. 10 Alternative splicing and 3 0 processing 1 at the RNA level generates two ST2 isoforms. 15 The transmembrane form, ST2L, acts as a receptor for IL-33, which is especially involved in modifying T helper (Th)2 cell-mediated immunologic responses.
14 Moreover, ST2 was recently shown to be expressed on adipose tissue macrophages. 16 Soluble ST2 (sST2) might act as a decoy receptor regulating or neutralizing the activity of circulating IL-33. However, sST2 is also linked to chronic inflammation by so far unknown mechanisms and is a prognostic biomarker for acute and chronic heart failure. [17] [18] [19] [20] IL-33 is known to activate mast cells, basophils, eosinophils and natural killer cells, and promotes inflammatory and autoimmune diseases. 11, 21 On the other hand, IL-33 is cardioprotective and reduces atherogenesis. [22] [23] [24] Moreover, IL-33 administration was shown to decrease fat mass while increasing fat-free body mass, and to improve the insulin sensitivity of obese mice. 25 IL-33 polarizes macrophages towards the alternatively-activated M2 type 26 and, analogously, T-cells towards Th2 cells. 14 Of note, expression of surface markers on human adipose tissue macrophages resembles an M2-like phenotype, while, uniquely, they secrete high amounts of inflammatory cytokines. 27 In mice, high-fat diet feeding shifts cytokine expression of adipose tissue macrophages from M2-to M1-like patterns 28 and weight reduction is reported to promote the occurrence of M2-like macrophages in adipose tissue of obese patients. 29 However, mechanisms leading to M1/M2 polarization in humans and mice, and their regulation by diet and weight gain is unclear. Strikingly, a role of T-cells in initiating obesity-induced adipose tissue inflammation and consequent insulin resistance that may involve a shift from Th2 to Th1, in homology to the M2/M1 shift as mentioned above, has been reported. 30 Altogether, few data exist on the expression of IL-33 and its receptor ST2 in adipose tissue, and the role of this functional pair in obesity-driven inflammation including M1/M2 and Th1/Th2 polarization of macrophages and T cells, respectively, are features of currently highest interest. Therefore, we aimed to investigate the impact of obesity on IL-33 and ST2 expression as well as the cell types involved to obtain information on the specific role of IL-33 in adipose tissue inflammation. We show that IL-33 and ST2 are markedly elevated in omental and subcutaneous adipose tissue of severely obese humans and in diet-induced obese mice, but not in leptin receptor-deficient obese mice. Also, sST2, but not IL-33 serum levels were elevated in severe obesity. Endothelial cells were identified as the main source for IL-33 and its receptor ST2 in the adipose tissue. Strikingly, in the adipose tissue of severely obese subjects, IL-33 expression strongly correlated with expression of leptin.
MATERIALS AND METHODS

Human samples
Omental (taken from the greater omentum as a commonly investigated source for visceral, intra-abdominal adipose tissue) and subcutaneous adipose tissue, and serum samples were obtained from severely obese patients (BMI440, mean ¼ 53.0 ± 2.5 kg m À 2 ) who underwent laparoscopic bariatric surgery (n ¼ 20, 4 male, 16 female) and were matched for age and sex with lean to pre-obese/overweight control subjects (BMIo30, mean ¼ 25.2±0.7 kg m À 2 ) undergoing laparoscopic cholecystectomy (n ¼ 15), fundoplication (n ¼ 3), resection of liver cysts (n ¼ 1) or partial colon resection (n ¼ 1). Further characteristics of the study population are given in Zeyda et al. 31 From the severe-obese patients, also muscle biopsy samples devoid of adjacent tissue were taken from the left transversalis muscle in the paraumbilical region during the laparoscopic procedure. Oil Red O staining of these sections revealed considerable amount of intramuscular lipids, while intermuscular adipose tissue was not present on the sections analyzed. Omental adipose tissue obtained from four additional obese patients was used for tissue fractionation. Adipose tissue samples were taken from similar locations in all patients. Criteria for exclusion were the presence of any infectious, inflammatory, neoplastic or systemic disease, diabetes (excluded by fasting plasma glucose or the use of anti-diabetic drugs) or other uncontrolled endocrine disease, and the current use of antibiotics, anti-inflammatory or anti-obesity drugs. The study was approved by the ethics committee of the Medical University of Vienna. All subjects gave written informed consent before taking part in the study.
Murine adipose tissue
To generate diet-induced obesity, male C57BL/6J mice (Charles River Laboratories, Sulzfeld, Germany) aged 7 weeks were placed for 20 weeks on a high-fat (60 kcal percent fat, D12492; Research Diets Inc., New Brunswick, NJ, USA) and low-fat diet (10 kcal percent fat, D12450B; Research Diets Inc.) to induce obesity and to serve as lean controls, respectively. Mice had free access to food and water. After 20 weeks on diet, mice were killed by cervical dislocation. Male diabetic (db/db) mice and their non-diabetic littermates (db/ þ ) were purchased from Charles River Laboratories Inc. at 7 weeks of age and maintained under standard conditions. After the mice were euthanized, adipose tissue was immediately snap frozen in liquid nitrogen and kept at À 80 1C until isolation of total RNA. A total of 20 mice were used for each group. The study protocols were approved by the local ethics committee for animal experiments, and followed the guidelines on accommodation and care of animals formulated by the European Convention for the Protection of the Vertebrate Animals Used for Experimental and Other Scientific Purposes.
Adipose tissue fractionation
Crude vessels were manually isolated from human omental adipose tissue, which was subsequently cut into small pieces, washed in phosphatebuffered saline, and 0.5 g tissue per ml and digested with 2 mg ml ) by means of flow cytometry using fluorochrome-conjugated monoclonal antibodies (mAbs) from BD Biosciences, except CD144-PE, which was purchased from Beckman-Coulter (Brea, CA, USA). All fractions were lysed and stored in Trizol reagent (Sigma-Aldrich) for subsequent RNA isolation.
From murine epididymal white adipose tissue adipocytes and SVC were prepared as described above, with the modification of using 0.03 mg ml
Liberase Blendzyme 3 (Roche, Basel, Switzerland) and 50 U/ml DNase I (Sigma-Aldrich) for digestion. Macrophages, T cells and SVC depleted of those were isolated by flow cytometry using F4/80-PE (Cedarlane, Burlington, ON, Canada) and CD3-Fitc (BD Biosciences) antibodies, respectively.
Quantitation of gene expression
Quantitation of gene expression. Total RNA was prepared by disrupting adipose tissue in TRIzol reagent (Invitrogen) with a tissue homogenizer followed by RNA isolation according to the manufacturer's instructions. RNA was reverse transcribed into cDNA by Superscript II using random hexamer priming. Quantitative real-time-PCR was carried out using FAM-TAMRA-labeled commercial Assays-on-Demand specific for IL-33, ST2 and leptin (Applied Biosystems, Foster City, CA, USA) normalized to ubiquitin (UBC) as a well-proven housekeeping gene. sST2 and ST2L were determined using LightCycler TaqMan master mix (Roche) and primers designed with the Roche Universal ProbeLibrary Assay Design Center (http://www.universalprobelibrary.com/). For ST2L 5 0 -gaaatacctgagactgggt gatttat-3 0 and 5 0 -gaagtgcctgcctttgctt-3 0 ,and for sST2 5 0 -gggagagatatgc tacctggag-3 0 and 5 0 -cgcctgctctttcgtatgtt-3 0 were used as forward and reverse primers, respectively. Specific mRNA expression was calculated using the DDC T method.
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Immunoblotting Human omental adipose tissue (300 mg) was homogenized and lysed on ice for 30 min in 0.5 ml TBS, pH 7.4, containing 1% Triton X-100 and protease inhibitors. The tissue extract was cleared from fat, nuclei and debris by centrifugation, and identical amounts of protein as detected by BCA assay (Pierce, Rockford, IL, USA) were separated by SDS-PAGE and blotted onto polyvinylidene fluoride membranes (Amersham, Little Chalfont, UK). IL-33 and b-actin as a loading control were detected by mouse monoclonal anti-IL-33 IgG (clone 4E9, Abcam, Cambridge, UK) and rabbit polyclonal anti-b-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and respective secondary antibodies according to standard procedures.
Immunofluorescence
Paraffin-embedded 5-mm sections of omental adipose tissue fixed in 4% paraformaldehyde were deparaffinized in xylene, and rehydrated in a series of descending concentrations of ethanol. Antigen retrieval was performed by boiling in 100 mM citrate buffer of pH 6. Sections were stained using mouse anti-CD31 mAb (DAKO no. IR610, 1:20) and rabbit anti-IL-33 Ab (Sigma-Aldrich, HPA024426, 1:200) or respective isotype controls and respective secondary antibodies as well as DAPI (SigmaAldrich) to detect nuclei according to standard procedures. Pictures were taken with a VANOX AHBT3 microscope (Olympus, Tokyo, Japan).
Frozen 20-mm sections of omental adipose tissue and skeletal muscle were fixed in acetone and endogenous peroxidases were quenched with 2% H 2 O 2 in phosphate-buffered saline. Following blocking (2% BSA, 2% goat serum, 0,1% Tween20 in phosphate-buffered saline), slides were stained using rabbit anti-IL33 pAb (Acris no. AP08936PU-N, 1:100) and mouse anti-CD144 mAb (BD Pharmingen no. 555661, 1:200) or adequate isotype controls. After washing, slides were incubated with goat-anti-rabbit HRP (Invitrogen) and goat-anti-mouse Alexa488 (Invitrogen) for 30 min. Subsequently, tyramid signal amplification was performed in 0.1 M borate buffer using rhodamine-tyramid, synthesized in our lab from NHS-rhodamine (Pierce) and tyramine-HCl (Sigma-Aldrich). Nuclei were stained with DAPI (Sigma-Aldrich). Pictures were taken with a ZEISS LSM 700 laser scan microscope (Carl Zeiss, Jena, Germany).
Quantitation of serum proteins
Commercial ELISA kits were used to quantitate IL-33 and soluble ST2 (Apotech/Enzo Life Sciences (Farmingdale, NY, USA) and R&D Systems (Minneapolis, MN, USA), respectively) in serum samples according to the manufacturers' instructions.
ST2 surface expression SVC of omental adipose tissue were stained using PE-conjugated anti-ST2 mAb (MBL Medical & Biological Laboratories, Nagoye, Japan) simultaneously with FITC-conjugated anti-CD31 and APC-conjugated CD34 or FITC-conjugated anti-CD14 and APC-conjugated anti-CD3 mAbs (all BD Biosciences) according to standard procedures.
Statistics
All data are given as mean ± s.e.m. Groups were compared by unpaired two-tailed Student's t-test. Correlations were analyzed non-parametrically by Spearman's rank correlation. To determine the correlation of leptin and IL-33 gene expression independently of age, the respective DDC T values were used in a partial correlation with age as the control variable. P valueso0.05 were considered statistically significant. All statistics were calculated using the SPSS 15.0 software (Chicago, IL, USA).
RESULTS
IL-33 expression in the adipose tissue is increased in obesity Human severe obesity was associated with an approximately threefold increase in IL-33 expression in omental as well as subcutaneous adipose tissue (Po0.01; Figure 1a) as compared with the control group. Immunoblotting confirmed the presence of IL-33 at protein level, and its increase in omental adipose tissue of severely obese humans (Figure 1b) . IL-33 serum concentrations, however, were unaltered in obesity (Figure 1c) .
Furthermore, we analyzed IL-33 regulation in commonly used murine models of obesity. Therefore, C57BL/6J mice were fed a high-fat diet for 20 weeks, which resulted in an average weight of 50.6 ± 1.1 g compared with 32.9 ± 1.2 g of low-fat diet-fed controls. We found that diet-induced obesity caused a fivefold upregulation of IL-33 mRNA expression in epididymal white adipose tissue (Po0.01; Figure 1d) . However, as shown in Figure 1d , IL-33 gene expression was not altered in adipose tissue on leptin-receptordeficient mice (db/db; weight 43.7 ±1.7 g) compared with their lean littermates (db/ þ , 27.3 ± 1.4 g).
Adipose tissue IL-33 is mainly expressed in the vasculature Although IL-33 has already been shown to be expressed in human adipose tissue, 13 the distribution and proportional contribution of different cell types to IL-33 expression have not been analyzed yet. In order to investigate cellular sources of IL-33 we fractionated human omental adipose tissue into crude vessels, matrix, adipocytes and SVC. The latter were subfractionated into adipose tissue macrophages, monocytes, T-cells, vascular endothelial and progenitor cells. Our results show that IL-33 is highly expressed in crude vessels and matrix (Figure 2a IL-33 and ST2 expression in obesity M Zeyda et al nucleus as previously described for endothelial cells. 33 We could not determine obvious qualitative and quantitative differences between samples from control and severely obese patients by immunofluorescence stainings (data not shown).
To investigate the cellular sources of IL-33 in murine adipose tissue, epididymal adipose tissue was fractionated in adipocytes, adipose tissue macrophages, T-cells and remaining SVC. Confirming the human data, IL-33 expression was highest in the macrophage-depleted SVC fraction that consisted of preadipocytes and microvascular cells and undetectable in T-cells (Figure 2c) .
To investigate if IL-33 is generally closely associated with endothelial cells in different tissues of obese humans, we compared the IL-33 expression pattern in frozen adipose tissue and muscle sections from same donors. In adipose tissue, IL-33 and the endothelial cell marker CD144 co-localized to a large extent (Figure 3a) . Thus, by using a different embedding technique and different antibodies, we strongly confirmed the results obtained with paraffin-embedded adipose tissue shown in Figure 2b . In contrast, in muscle IL-33 was not confined to the proximity of endothelial cells but was mainly detected in or close to the sarcolemma of muscle fibers (Figure 3b) . Thus, the association of IL-33 protein expression with endothelial cells depends on the tissue. Interestingly, in rare regions that were detectable in two out of four investigated donors, we found a profound expression of IL-33 within fibers (Figure 3c ).
Obesity increases ST2 expression in adipose tissue and soluble ST2 serum concentrations Similar to its ligand IL-33, ST2 expression was markedly increased in severe obesity in omental as well as subcutaneous human adipose tissue (Po0.01; Figure 4a ). Discrimination between RNA for the transmembrane form ST2L (Figure 4b ) and the soluble ST2 form sST2 (Figure 4c ) revealed that both forms were regulated in a similar manner. Moreover, severe obesity was associated with a significant increase of approximately 1.5-fold in serum sST2 concentration (Figure 4d) . Also, in mice ST2 expression was regulated similarly as IL-33. We found that diet-induced obesity caused an upregulation of ST2 mRNA expression in epididymal white adipose tissue, whereas in genetic obesity, ST2 gene expression in adipose tissue was not altered (Figure 4e) . ST2 surface expression is detectable exclusively on endothelial cells in human adipose tissue Analyzing the fraction of human omental adipose tissue described above, we found ST2 mRNA mainly in SVC and within SVC most pronounced in T-cells and endothelial cells (Figure 5a) . As activation by IL-33 demands ST2 expression on the cell surface, we analyzed ST2 surface expression of SVC isolated from human omental adipose tissue by flowcytometry. The results revealed that only endothelial cells (CD34 þ CD31 þ ) were clearly positive for ST2, while ST2 could not be detected on the surface of any other cell type including T-cells (CD3 þ ; Figure 5b ). In murine adipose tissue, interestingly, analysis of cell fractions showed that ST2 gene expression was predominant in T-cells, while it was low in adipocytes and macrophages (Figure 5c ).
Leptin correlates with IL-33 expression
To investigate a potential link between IL-33 expression and other parameters involved in obesity, we analyzed correlations in the group of severely obese patients between omental IL-33 gene expression and other investigated anthropometric and laboratory parameters. 31 IL-33 gene expression correlated significantly only with leptin gene expression (Spearman's r ¼ 0.516; P ¼ 0.020; Figure 6 ) and with age (r ¼ 0.456; P ¼ 0.043; correlations were calculated using DDC T values; hence the positive value for r here indicates a negative correlation of age with the IL-33 gene expression levels). The correlation of IL-33 with leptin was still significant when corrected for age (partial correlation coefficient ¼ 0.572; P ¼ 0.011). In subcutaneous adipose tissue, the correlation between leptin and IL-33 gene expression was even more pronounced (Spearman's r ¼ 0.746; Po0.001). Moreover, the IL-33 gene expression levels in subcutaneous adipose tissue correlated with those of CD68 (r ¼ 0.578; P ¼ 0.008) and CD3 (r ¼ 0.581; P ¼ 0.007), which are markers for macrophage and T cell abundance, respectively. Neither in omental nor in subcutaneous adipose tissue was IL-33 gene expression correlated with the Th1/Th2 balance, as detected by the TBX21/GATA3 ratio. 
DISCUSSION
The results of this study show that both IL-33 and ST2 gene expression is elevated in the adipose tissue of severely obese humans and high fat-fed mice, and that the IL-33/ST2 system in human adipose tissue is predominantly detectable in the vascular endothelium and correlates with leptin expression. Although it has been shown that IL-33 is expressed in adipocytes, preadipocytes 13 and endothelial cells, 12 by directly comparing cellular fractions of the adipose tissue, we here demonstrated that endothelial cells are the predominant cell type to express this cytokine in the adipose tissue and that this expression pattern is particular for adipose tissue, at least if compared with the muscle of the same donors. Some muscle fibers exceptionally strongly expressed IL-33 ( Figure 3c ). Intramuscular triglyceride content did not correlate with IL-33 expression (data not shown). Hence, it remains unknown under which conditions this strong IL-33 expression occurs, and/or if a specific fiber type is specifically highly expressing IL-33. Generally, the role of muscle IL-33 in obesity remains to be elucidated in future studies.
A striking finding of this study is the strong correlation between IL-33 and leptin expression in the adipose tissue of obese patients. Also, the fact that db/db mice, with disrupted leptin function, show no increase in IL-33 during obesity emphasizes the tight link between leptin and obesity-driven upregulation of IL-33 expression. Hence, in this respect only the diet-induced but not the genetic mouse model used here reflects the situation in humans. Of note, leptin is known to induce oxidative stress in endothelial cells, to alter their function by increasing inflammatory cytokine expression 34, 35 and to promote monocyte transmigration through endothelial cell layers. 36 Furthermore, we found leptin to induce IL-33 in human smooth muscle cells (Demyanets S, personal communication) . Hence, the data suggest that obesity could control IL-33 expression of adipose tissue endothelial cells via leptin. However, further work is needed to experimentally confirm this speculation in human adipose tissue endothelial cells.
In human adipose tissue, the IL-33 receptor ST2 was exclusively found on the surface of endothelial cells. Recently it was demonstrated that endothelial cells react to IL-33 by upregulating adhesive and inflammatory molecules. 37, 38 Moreover, IL-33 was shown to induce angiogenesis and to increase vascular permeability in human endothelial cells. 39 Therefore, our data suggest that IL-33 may contribute to endothelial cell activation and thus endothelial cell-mediated immune cell immigration and activation in obesity via an autocrine mechanism even though we do not have direct evidence of IL-33 secretion in adipose tissue. As IL-33 mRNA, similar to the mRNA of the IL-1 family members, IL-1b and IL-18, is translated without a signal sequence for secretion, 10 generally more detailed information about processing and secretion of IL-33 needs to be acquired. Also, the proposed role of IL-33 as an 'alarmin' secreted from necrotic cells 10 could have a role in stressed and inflamed adipose tissue as existent in obesity.
Selectively in murine adipose tissue, T-cells are the cell type by far highest expressing ST2, at least at mRNA level, and therefore may represent the main target of IL-33. Hence, IL-33 could control Th2 polarization of T-cells in mice, and thereby counteract obesityinduced inflammation, which could explain the positive effects of IL-33 on insulin sensitivity 25 via ST2-mediated Th2 pool expansion. However, a recent study indicates that IL-33 acts on innate rather than adaptive immune cells. 21 Accordingly, ST2 protein expression was previously shown also on murine adipose tissue macrophages. 16 However, the ST2 staining adipose tissue macrophages shown by Westcott et al. 16 may represent small amounts of ST2 as compared with endothelial cells and T-cells as suggested by our gene expression analysis. Despite the potential direct role on the immune cells involved in obesity in mice, our data in humans do not support the conception that IL-33 might contribute to the adipose tissue Th1/Th2 T-cell and M1/M2 macrophage balance, which depend on body weight. [29] [30] [31] 40 Moreover, IL-33 administration caused a loss of fat mass and an increase in fat-free mass in mice that could underlie the observed effects on insulin sensitivity. 25 Thus, the role of IL-33 action on T-cells and macrophages in the context of adipose tissue inflammation and associated metabolic consequences remains unclear and may be species dependent.
Albeit in a small cohort, we show here for the first time that also sST2 plasma levels are elevated in obesity in humans, while we could not detect alterations in IL-33 serum concentrations. Furthermore, our data demonstrate that transmembrane ST2L and soluble sST2 are both upregulated in the adipose tissue by obesity. Serum sST2 levels, however, did not directly correlate with adipose tissue gene expression in the obese (data not shown). Thus, it remains unclear whether plasma sST2 is in any way related to adipose tissue expression of sST2. sST2 is a risk factor for both chronic and acute heart failure, [17] [18] [19] [20] and we could speculate that enhanced adipose expression of sST2 might contribute to diabetic heart failure and that sST2 may be used as a biomarker in this respect. On the other hand, there is evidence suggesting that sST2 is a decoy receptor for IL-33 and thus neutralizes IL-33 effects. 23 Therefore, it will be important to further evaluate the complex pro-and anti-inflammatory potential 24 of systemic and tissue IL-33 and the biological importance of the sST2/IL-33 balance, particularly in obesity.
Altogether, we found expression of IL-33 and its receptor ST2 elevated in obesity, indicating augmentation of a presumed autocrine loop in endothelial cells of the human adipose tissue vasculature. Moreover, our results suggest that leptin triggers the obesity-driven elevation of IL-33 gene expression. By activating adipose tissue endothelial cells, IL-33 could contribute to obesitydriven adipose tissue inflammation, whereas a systemic role of IL-33 in obesity-associated disorders appears unlikely. 
